title: Prostaglandin E synthase is upregulated by Gas6 during cancer-induced venous thrombosis.
abstract: Venous thromboembolism is a common complication of cancer. Based on recent evidence that (1) growth arrest-specific 6 (Gas6) regulates the expression of tissue factor during venous thrombosis, and (2) cancer promotes a procoagulant milieu, we hypothesize that Gas6 may be involved in cancer-induced coagulopathy. Venous thrombi were induced in both wild-type (WT) and Gas6-deficient ((-/-)) mice with cancer. WT mice with cancer developed larger thrombi than their healthy counterparts; these larger thrombi induced by cancer were not seen in Gas6(-/-) mice. Whole genome microarray analysis of differential gene expression in WT and Gas6(-/-) endothelial cells exposed to M27 murine lung carcinoma cells reveal that Gas6 increases prostaglandin E synthase (Ptges) expression in endothelial cells. This was confirmed using real-time polymerase chain reaction and immunofluorescence staining. Culture of WT endothelial cells with M27 increases the secretion of prostaglandin E2 (PGE2), the enzymatic product of Ptges, in WT but not in Gas6(-/-) endothelial cells. In WT endothelial cells, Ptges expression was regulated through extracellular signal-regulated kinase 1/2 phosphorylation (ERK1/2). In vitro, PGE2 activates platelets after binding to its receptor, EP3. In vivo, EP3 receptor antagonism reversed the effect of cancer-induced thrombosis in WT mice. These results show that Gas6, through upregulation of PGE2, contributes to cancer-induced venous thrombosis.
authors.affiliation: Lady Davis Institute and.
authors.forename: Meghedi N
authors.initials: MN
authors.lastname: Aghourian
authors.affiliation: Lady Davis Institute and Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada.
authors.forename: Catherine A
authors.initials: CA
authors.lastname: Lemarié
authors.affiliation: Lady Davis Institute and.
authors.forename: Francois-René
authors.initials: FR
authors.lastname: Bertin
authors.affiliation: Lady Davis Institute and Department of Medicine, Jewish General Hospital, McGill University, Montreal, QC, Canada.
authors.forename: Mark D
authors.initials: MD
authors.lastname: Blostein
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D015232:Dinoprostone / Q000009:adverse effects / Q000378:metabolism; D015971:Gene Expression Regulation, Enzymologic; D015972:Gene Expression Regulation, Neoplastic; D036341:Intercellular Signaling Peptides and Proteins / Q000235:genetics / Q000502:physiology*; D019746:Intramolecular Oxidoreductases / Q000235:genetics* / Q000378:metabolism; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D018345:Mice, Knockout; D009369:Neoplasms / Q000150:complications* / Q000235:genetics / Q000473:pathology; D000071876:Prostaglandin-E Synthases; D015854:Up-Regulation; D020246:Venous Thrombosis / Q000209:etiology* / Q000235:genetics / Q000473:pathology; D000099255:Growth Arrest-Specific Protein 6
chemical_list: D015232:Dinoprostone; D036341:Intercellular Signaling Peptides and Proteins; D019746:Intramolecular Oxidoreductases; D000071876:Prostaglandin-E Synthases; D000099255:Growth Arrest-Specific Protein 6; C000605865:Ptges protein, mouse